Ligocyte Acquired By Japanese Firm
Bozeman, Montana-based biopharmaceuticals developer LigoCyte Pharmaceuticals has been acquired by Japanese firm Takeda Pharmaceutical Co., Takeda said this morning. Takeda will pay $60M for LigoCyte, giving it access to LigoCyte's norovirus vaccine, aimed at treating gastroenteritis. LigoCyte is venture backed by Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture partners, and MC Life Sciences Ventures.
posted on Friday, October 5, 2012
Related companies:
LigoCyte Pharmaceuticals
Related stories:
> LigoCyte Pharmaceuticals Raises $28M
> LigoCyte Pharmaceuticals Adds More Funding
> LigoCyte Pharmaceuticals Raises $6.5M
> PositiveWare Signs Japanese Partnership
> Gnip In Japanese Partnership
Techrockies.com Home